Eye Signs of Thyrotoxicosis

Thyrotoxicosis (especially Graves' disease) produces a set of classic ocular findings. These fall into two categories: signs due to sympathetic overactivity (seen in any thyrotoxicosis, reversible with treatment) and true infiltrative ophthalmopathy (Graves' orbitopathy/thyroid eye disease - an autoimmune process specific to Graves' disease, not simply from excess thyroid hormone).

1. Mechanism

Lid retraction/lid lag - caused by overactivity of Müller's muscle (the sympathetically-innervated smooth muscle part of levator palpebrae superioris), driven by catecholamine excess. This is functional, not structural, and improves once the patient is euthyroid.
Exophthalmos (proptosis) and infiltrative signs - an autoimmune process. TSH-receptor autoantibodies cross-react with receptors on orbital fibroblasts and retrobulbar fat, triggering fibroblasts to secrete glycosaminoglycans (hyaluronic acid). These are osmotically active and cause edema, engorgement and eventual fibrosis of the extraocular muscles and orbital fat, pushing the globe forward (Cummings Otolaryngology; Harrison's Principles of Internal Medicine, 22E).

2. The Classic Eye Signs (Cardinal Sign #1 of Primary Toxic Goitre)

There are four broad categories, each of which may be unilateral or bilateral - S Das, A Manual on Clinical Surgery, 13th Ed.

(i) Lid retraction - the upper lid sits higher than normal while the lower lid stays in normal position. Distinct from exophthalmos.

(ii) Exophthalmos - forward protrusion of the eyeball from fat/edema/cellular infiltration in the retro-orbital space; sclera becomes visible below the iris first, then above it. Several eponymous signs are tested for this:

Sign	Finding
Von Graefe's sign	Upper eyelid lags behind the eyeball when the patient looks downward (classic "lid lag")
Joffroy's sign	Absence of forehead wrinkling when the patient looks up with the face tilted down
Stellwag's sign	Staring look with infrequent blinking and widened palpebral fissure, from toxic contraction of striated fibers of levator palpebrae superioris
Moebius' sign	Inability/failure to converge the eyeballs (convergence weakness)
Dalrymple's sign	Visible upper sclera due to upper eyelid retraction

(iii) Ophthalmoplegia - weakness of extraocular muscles from edema and cellular infiltration, most often affecting superior rectus, lateral rectus, and inferior oblique, preventing the patient from looking up and out.

(iv) Chemosis - conjunctival edema; the conjunctiva becomes thickened, boggy and crinkled, caused by obstruction of venous/lymphatic drainage from raised retro-orbital pressure.

In severe/progressive ("malignant") exophthalmos, extensive chemosis and periorbital edema can obscure the true degree of proptosis, and there is risk of exposure keratitis and optic nerve compression leading to visual loss (S Das; Schwartz's Principles of Surgery, 11th Ed).

3. Clinical Grading and Complications

Graves' ophthalmopathy (thyroid eye disease, TED) is the most common cause of both unilateral and bilateral proptosis in adults (Kanski's Clinical Ophthalmology, 10th Ed).
Restriction of upward gaze occurs from infiltration/fibrosis of the inferior rectus muscle; lateral gaze restriction from medial rectus involvement (Rosen's Emergency Medicine).
Severity is often graded clinically (e.g. NOSPECS, or the EUGOGO activity/severity scoring), assessing lid signs, soft tissue involvement, proptosis, extraocular muscle restriction, corneal exposure, and sight (optic nerve compression) - Goldman-Cecil Medicine.
Optic nerve compression from crowded orbital apex is the most feared complication, causing progressive visual loss - it is an indication for urgent orbital decompression.

4. Key Clinical Point

Lid retraction and lid lag are sympathetic/functional signs found in thyrotoxicosis of any cause and resolve with treatment of hyperthyroidism. True exophthalmos, chemosis, and ophthalmoplegia reflect Graves' orbitopathy specifically, are immune-mediated, and can persist or even progress independent of thyroid hormone control - sometimes worsening after radioiodine therapy, as noted in classic teaching (S Das).

Recent Evidence Note

Current management of active/moderate-to-severe Graves' orbitopathy centers on glucocorticoids (IV pulse preferred over oral), with newer biologic options:

A 2024 systematic review (PMID: 38886120) found rituximab and other immunomodulators show favorable clinical/quality-of-life outcomes compared with steroids alone in some populations, though evidence quality is mixed.
A 2024 meta-analysis (PMID: 38273269) supports combined glucocorticoid + cyclophosphamide regimens improving outcomes in more refractory disease.
A 2025 systematic review (PMID: 40580399) is exploring circulating miRNAs as biomarkers for disease activity/prognosis - still investigational, not yet in routine practice.

These don't contradict the classical clinical sign teaching above but reflect evolving treatment options for active orbitopathy beyond glucocorticoids alone (e.g., teprotumumab, an IGF-1R inhibitor, now used in some countries for active moderate-severe TED).

This is a shared conversation. Sign in to Orris to start your own chat.